| Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib (NCT02621047) | Hoffmann-La Roche | 2015-12-04 |
| A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine (NCT02611505) | Janssen Research & Development, LLC | 2015-11-30 |
| Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment (NCT02581592) | Mylan Inc. | 2015-11-01 |
| A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function (NCT02524717) | Aragon Pharmaceuticals, Inc. | 2015-08-13 |
| INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function (NCT02474537) | Novartis Pharmaceuticals | 2015-06-12 |
| Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment (NCT03160014) | Jiangsu HengRui Medicine Co., Ltd. | 2015-06-01 |
| PK Study of Sotagliflozin in Subjects With Hepatic Impairment (NCT02471274) | Lexicon Pharmaceuticals | 2015-06-01 |
| Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function (NCT02452801) | Alkermes, Inc. | 2015-05-01 |
| A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function (NCT02372084) | Novartis Pharmaceuticals | 2015-04-21 |
| Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment (NCT02367872) | Takeda | 2015-03-01 |
| A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics (NCT02286609) | PTC Therapeutics | 2014-12-01 |
| Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) (NCT02115347) | Merck Sharp & Dohme LLC | 2014-09-19 |
| Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment (NCT02244827) | Wockhardt | 2014-09-01 |
| Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline (NCT02256033) | Kyowa Kirin Co., Ltd. | 2014-08-01 |
| Influence of Microfiltered-seawater Supplementation and Variable Resistance Training in Blood Pressure, Oxidative Stress, Hepatic, and Renal Biomarkers in Older Women (NCT06600243) | University of Valencia | 2014-05-01 |
| PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers (NCT02121860) | Conatus Pharmaceuticals Inc. | 2014-04-01 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment (NCT02150733) | Daiichi Sankyo | 2014-04-01 |
| MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function (NCT02050815) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2014-03-01 |
| Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects (NCT02095587) | SecuraBio | 2014-03-01 |
| A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers (NCT03832426) | R-Pharm | 2013-11-08 |
| Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment (NCT01949545) | Amgen | 2013-10-01 |
| Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers (NCT02004587) | LG Life Sciences | 2013-09-01 |
| Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients (NCT01887301) | Jazz Pharmaceuticals | 2013-07-01 |
| EVP-6124 Hepatic Impairment Study (NCT01984736) | FORUM Pharmaceuticals Inc | 2013-06-01 |
| Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects (NCT01888393) | Vertex Pharmaceuticals Incorporated | 2013-06-01 |
| Hepatic Impairment Trial of Obeticholic Acid (NCT01904539) | Intercept Pharmaceuticals | 2013-06-01 |
| A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function (NCT01863784) | Janssen Research & Development, LLC | 2013-04-01 |
| An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment (NCT01790607) | Ono Pharma USA Inc | 2013-02-01 |
| An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers (NCT01767103) | ApoPharma | 2013-01-01 |
| Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment (NCT01762462) | Bristol-Myers Squibb | 2012-12-01 |
| A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment (NCT01767948) | Janssen Research & Development, LLC | 2012-12-01 |
| Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function (NCT01732263) | Shire | 2012-11-09 |
| Pharmacokinetics of BAF312 in Patients With Hepatic Impairment (NCT01565902) | Novartis Pharmaceuticals | 2012-10-01 |
| A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers (NCT01621633) | Novartis Pharmaceuticals | 2012-09-01 |
| Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects (NCT01846455) | Indivior Inc. | 2012-09-01 |
| A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment (NCT01600976) | Janssen Infectious Diseases BVBA | 2012-06-01 |
| A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function (NCT01631097) | AVEO Pharmaceuticals, Inc. | 2012-05-01 |
| Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment (NCT01594957) | Novartis Pharmaceuticals | 2012-04-01 |
| The Investigation of the Causes of Hepatic Dysfunction in the Postoperative Period During Open-heart Surgeries (NCT04271098) | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | 2012-01-01 |
| A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function (NCT01516047) | Janssen Research & Development, LLC | 2012-01-01 |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function (NCT01443481) | Novartis Pharmaceuticals | 2011-11-01 |
| Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment (NCT01727128) | Novartis Pharmaceuticals | 2011-10-01 |
| Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects (NCT01493869) | Exelixis | 2011-09-01 |
| A PK and Safety Study in Subjects With Hepatic Impairment (NCT01431833) | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2011-08-01 |
| Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment (NCT01419457) | MDVI, LLC | 2011-08-01 |
| Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects (NCT01433458) | Novartis Pharmaceuticals | 2011-07-01 |
| A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg) (NCT02421042) | Eisai Inc. | 2011-06-01 |
| A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects (NCT01456663) | Novartis Pharmaceuticals | 2011-05-01 |
| A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment (NCT01319279) | Cephalon | 2011-04-01 |
| PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function (NCT01429337) | Novartis Pharmaceuticals | 2011-03-07 |
| Pharmacokinetics of AGO178 in Participants With Liver Impairment (NCT01531309) | Novartis Pharmaceuticals | 2011-02-08 |
| Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment (NCT02242734) | Zogenix, Inc. | 2011-02-01 |
| Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects (NCT05391724) | Jazz Pharmaceuticals | 2011-02-01 |
| Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment (NCT01271387) | Vanda Pharmaceuticals | 2011-01-01 |
| GSK1349572 Hepatic Impairment Study (NCT01231529) | ViiV Healthcare | 2010-11-19 |
| A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function (NCT01222455) | AstraZeneca | 2010-10-01 |
| Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers (NCT01529294) | Novartis Pharmaceuticals | 2010-08-01 |
| A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers (NCT01146938) | Boryung Pharmaceutical Co., Ltd | 2010-05-01 |
| Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment (NCT01134185) | Movetis | 2010-05-01 |
| Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment (NCT01126086) | Sanofi | 2010-05-01 |
| BG9928 in Subjects With Hepatic Impairment (NCT00858156) | Biogen | 2009-04-01 |
| A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics (NCT01027169) | Newron Pharmaceuticals SPA | 2009-04-01 |
| Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects (NCT00812305) | Pacira Pharmaceuticals, Inc | 2009-01-01 |
| A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment (NCT00768209) | VIVUS LLC | 2008-10-01 |
| Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment (NCT00828932) | Eisai Inc. | 2008-08-01 |
| TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function. (NCT00736905) | Tibotec Pharmaceuticals, Ireland | 2008-06-01 |
| Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment (NCT00672581) | AstraZeneca | 2008-04-01 |
| Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours (NCT00621725) | AstraZeneca | 2008-01-01 |
| A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function (NCT00956306) | Dong-A Pharmaceutical Co., Ltd. | 2007-11-01 |
| Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants (NCT00819468) | Shire | 2007-07-26 |
| Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox. (NCT00432627) | Novartis Pharmaceuticals | 2006-12-01 |
| A Comparison Between Child-Pugh and Albumin-Bilirubin Scores (NCT03534843) | Huazhong University of Science and Technology | 2005-01-01 |
| Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment (NCT00162097) | Bristol-Myers Squibb | 2004-11-01 |
| A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function (NCT00791284) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-08-01 |